



3D growth of invasive BC cell lines on Matrigel (6mg/1mg/ml)

MDA-MB-231 (branched, invasive) MBA-MB-435S (branched-stellate, invasive)



MCF10A (duct-like pattern, non invasive)
control

BT-549 (stellate, invasive)



all x100

Fig. 1

BEST AVAILABLE COPY

Fig. 2







Fig. 3A



Corr: 0.51.

TMT L (b)
 CM44 (b)
 TITN2 (3a) (b)
 RDG2 (b)
 Caveolin2 (b)
 Caveolin1 (b)
 TITN2 (2b) (b)
 Ufo/asf L (b)
 MOP14 (12a) (b)
 HDAM12 (d)
 M-CSF (b)
 1vn L (b)
 fvn L (b)
 SIRPalpha1 (b)
 Gas6 (b)
 EGR1 (b)
 Stat5b (b)
 Stat5a (b)




[illegible]

Fig. 3B



TERT L (b)
 ERG2 (b)
 ERG1 (b)
 Stat6b (b)
 Stat6a (b)
 Gas6 (b)
 Info/ad L (b)
MDM13 (13a) (b)
 MDM12 (d)
 MDM2 (b) (b)
 Vimentin (b)
 TIMP3 (3a) (b)
 JORGE (b)
 EPIR2 L (b)
 MDM17 (b)
 abl L (b)
 M-CSF (b)
 Caveolin2 (b)
 Caveolin1 (b)
 CD44 (b)
 SRC (b) (b)
 fyn L (b)
 Iva L (b)
 SIRTpa1a1 (b)
 SIRT1 (b)
 MDM-1 (b)



Analysis of expression RTK AXL and GAS by Northern blot




Fig. 4

The 3D outgrowth on Matrigel matrix a different invasive breast cancer cell lines (14 days)




Fig. 5A

All -dn-AXL clones growth as non invasive, pseudo acinar-fused cancer cells

x100



Fig. 5B

Wound assay



MDA-MB-435S, mock

10%FCS



MDA-MB435S-dnAXL, cl. 2



FCS+GAS6




Starvation 72h



MDA-MB-435S, mock treated by Ex-AXL antibody (ab): 3D growth on MM, 14 days



no ab treatment




+anti-GAS ab





+preimmune serum (R1)

(MDA-MB435S-dnAXL c12, 14 days on MM)



treatment by -Ex-AXL ab: fused outgrowth



(pseudo acinar or fused)

Fig. 6A

100 μ m




Fig. 6B

10/521410





Fig. 6C


The morphology of breast cancer cell line MCF7
with forced over-expression RTK AXL wt

mock


AXL wt



x100



x320



x320



Fig.7A




Fig. 7B

Figure 8




Figure 9




Figure 10





Figure 11



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.